Last reviewed · How we verify
NCT06157086: SEPROS
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
trial testing ofatumumab in Multiple Sclerosis (MS) in 302 participants. Participants enrolled and being followed up; not accepting new ones.
31 July 2026
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 302 |
| Start date | 21 December 2023 |
| Primary completion | 31 July 2026 |
| Estimated completion | 31 July 2026 |
| Sites | 49 locations across France |
Drugs / interventions tested
- ofatumumab (OFATUMUMAB) — full drug profile →
Conditions studied
- Multiple Sclerosis (MS) — all drugs for Multiple Sclerosis (MS) →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Adults 18 to 99, any sex, with Multiple Sclerosis (MS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06157086
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ofatumumab
Trials testing the same drug.
- NCT06551519 — A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofil · recruiting
- NCT06251986 — A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Mult · completed
- NCT06121349 — WOE of Anti-CD20 Therapies · completed
- NCT05627271 — The 'Wearing Off' Effect of DMT · completed
- NCT05090033 — Characterizing the Use of Ofatumumab in a Real World Setting · completed
Other recruiting trials for Multiple Sclerosis (MS)
Currently open trials in the same condition.
- NCT07526493 — Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media · Phase 1 · recruiting
- NCT06869278 — A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases · Phase 1 · recruiting
- NCT06053749 — An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimest · active not recruiting
- NCT06270641 — Increasing Physical Activity for Adults With Multiple Sclerosis (MS) · NA · recruiting
- NCT05359653 — Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy · Phase 1, PHASE2 · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06157086 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 6 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06157086.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing